3.連結財務諸表及び主な注記
(1)連結純損益及びその他の包括利益計算書
| | (単位:百万円) |
| 前連結会計年度 (自 2023年4月1日 至 2024年3月31日) | 当連結会計年度 (自 2024年4月1日 至 2025年3月31日) |
売上収益 | 301,965 | 300,004 |
売上原価 | △123,256 | △128,977 |
売上総利益 | 178,709 | 171,027 |
販売費及び一般管理費 | △91,529 | △87,967 |
研究開発費 | △25,416 | △24,103 |
製品に係る無形資産償却費 | △9,471 | △8,812 |
その他の収益 | 1,548 | 589 |
その他の費用 | △15,301 | △3,854 |
営業利益 | 38,541 | 46,880 |
金融収益 | 1,572 | 4,002 |
金融費用 | △2,664 | △2,716 |
持分法による投資損失 | △7,575 | △685 |
税引前当期利益 | 29,874 | 47,481 |
法人所得税費用 | △3,171 | △11,628 |
当期利益 | 26,703 | 35,853 |
その他の包括利益 | | |
純損益に振り替えられない項目: | | |
確定給付制度の再測定 | 1,829 | 358 |
その他の包括利益を通じて公正価値で測定する 金融資産の純変動 | △1,697 | △2,293 |
純損益に振り替えられる可能性のある項目: | | |
在外営業活動体の換算差額 | 12,272 | △2,650 |
キャッシュ・フロー・ヘッジ | △20 | 20 |
持分法適用会社におけるその他の包括利益に対する持分 | 902 | △2,325 |
その他の包括利益 | 13,285 | △6,889 |
当期包括利益合計 | 39,988 | 28,964 |
当期利益の帰属 | | |
親会社の所有者持分 | 26,642 | 36,256 |
非支配持分 | 60 | △403 |
当期利益 | 26,703 | 35,853 |
当期包括利益合計の帰属 | | |
親会社の所有者持分 | 39,991 | 29,340 |
非支配持分 | △3 | △376 |
当期包括利益合計 | 39,988 | 28,964 |
1株当たり当期利益 | | |
基本的1株当たり当期利益(円) | 72.59 | 103.98 |
希薄化後1株当たり当期利益(円) | 72.37 | 103.68 |
<コアベース>
E0094945360参天製薬株式会社SANTEN PHARMACEUTICAL CO., LTD.通期第3号参考様式 [IFRS](連結)IFRStrueCTECTE2024-04-012025-03-31FY2025-03-312023-04-012024-03-312024-03-311falsefalsefalse453602024-03-31jpigp_cor:ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember453602023-04-012024-03-31jpigp_cor:ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember453602023-03-31jpigp_cor:ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember453602024-04-012025-03-31jpigp_cor:ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember453602025-03-31jpigp_cor:ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember453602025-03-31jpigp_cor:EffectivePortionOfCashFlowHedgesIFRSMember453602024-04-012025-03-31jpigp_cor:EffectivePortionOfCashFlowHedgesIFRSMember453602024-03-31jpigp_cor:EffectivePortionOfCashFlowHedgesIFRSMember453602023-04-012024-03-31jpigp_cor:EffectivePortionOfCashFlowHedgesIFRSMember453602023-03-31jpigp_cor:EffectivePortionOfCashFlowHedgesIFRSMember453602025-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember453602025-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember453602025-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember453602025-03-31jpigp_cor:RetainedEarningsIFRSMember453602025-03-31jpigp_cor:TreasurySharesIFRSMember453602024-03-31jpigp_cor:ShareCapitalIFRSMember453602023-04-012024-03-31jpigp_cor:NonControllingInterestsIFRSMember453602023-04-012024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember453602023-04-012024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember453602023-04-012024-03-31jpigp_cor:ShareAcquisitionRightsIFRSMember453602023-04-012024-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember453602023-04-012024-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember453602023-04-012024-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember453602023-04-012024-03-31jpigp_cor:RetainedEarningsIFRSMember453602023-04-012024-03-31jpigp_cor:TreasurySharesIFRSMember453602023-04-012024-03-31jpigp_cor:CapitalSurplusIFRSMember453602023-04-012024-03-31jpigp_cor:ShareCapitalIFRSMember453602023-03-31jpigp_cor:NonControllingInterestsIFRSMember453602023-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember453602023-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember453602023-03-31jpigp_cor:ShareAcquisitionRightsIFRSMember453602023-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember453602023-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember453602023-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember453602023-03-31jpigp_cor:RetainedEarningsIFRSMember453602023-03-31jpigp_cor:TreasurySharesIFRSMember453602023-03-31jpigp_cor:CapitalSurplusIFRSMember453602023-03-31jpigp_cor:ShareCapitalIFRSMember453602025-03-31jpigp_cor:NonControllingInterestsIFRSMember453602025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember453602025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember453602025-03-31jpigp_cor:ShareAcquisitionRightsIFRSMember453602024-04-012025-03-31jpigp_cor:NonControllingInterestsIFRSMember453602025-03-31jpigp_cor:CapitalSurplusIFRSMember453602025-03-31jpigp_cor:ShareCapitalIFRSMember453602024-04-012025-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember453602024-04-012025-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember453602024-04-012025-03-31jpigp_cor:ShareAcquisitionRightsIFRSMember453602024-04-012025-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember453602024-04-012025-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember453602024-04-012025-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember453602024-04-012025-03-31jpigp_cor:RetainedEarningsIFRSMember453602024-04-012025-03-31jpigp_cor:TreasurySharesIFRSMember453602024-04-012025-03-31jpigp_cor:CapitalSurplusIFRSMember453602024-04-012025-03-31jpigp_cor:ShareCapitalIFRSMember453602024-03-31jpigp_cor:NonControllingInterestsIFRSMember453602024-03-31jpigp_cor:EquityAttributableToOwnersOfParentIFRSMember453602024-03-31jpigp_cor:OtherComponentsOfEquityIFRSMember453602024-03-31jpigp_cor:ShareAcquisitionRightsIFRSMember453602024-03-31jpigp_cor:ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember453602024-03-31jpigp_cor:FinancialAssetsMeasuredAtFairValueThroughOtherComprehensiveIncomeIFRSMember453602024-03-31jpigp_cor:RemeasurementsOfDefinedBenefitPlansIFRSMember453602024-03-31jpigp_cor:RetainedEarningsIFRSMember453602024-03-31jpigp_cor:TreasurySharesIFRSMember453602024-03-31jpigp_cor:CapitalSurplusIFRSMember453602025-05-13453602025-03-31453602024-04-012025-03-31453602024-03-31453602023-04-012024-03-31453602023-03-31iso4217:JPYxbrli:sharesxbrli:pureiso4217:JPY